IDEAYA Biosciences (IDYA) Net Margin (2020 - 2026)

IDEAYA Biosciences (IDYA) posted Net Margin of 3548.25% for Q1 2026, down 310.3% sequentially from 864.79% in Q4 2025.

IDEAYA Biosciences (IDYA) Net Margin (2020 - 2026) Analysis & Trends

IDEAYA Biosciences has reported Net Margin for 7 years, with the latest figure at 3548.25% in Q1 2026.

Quarterly Net Margin changed N/A year-over-year to 3548.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 186.03% (changed N/A YoY) and the FY2025 annual result came in at 161.98%, up 686089.0% from the prior year.
Net Margin retreated to 3548.25% in Q1 2026 per IDYA's latest filing, from 864.79% in the prior quarter.
Over five years, Net Margin peaked at 14.51% in Q3 2025 and troughed at 3548.25% in Q1 2026.
A 5-year average of 897.23% and a median of 638.92% in 2022 frame the typical range for Net Margin.
The sharpest annual moves came in 2024 and 2025: Net Margin sank 110349 bps in 2024, then jumped 123752 bps in 2025.
Over 5 years, Net Margin stood at 629.69% in 2022, then tumbled by 59 bps to 998.83% in 2023, then plunged by 110 bps to 2102.31% in 2024, then soared by 59 bps to 864.79% in 2025, then slumped by 310 bps to 3548.25% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 3548.25%, 864.79%, and 14.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	IDEAYA Biosciences	3.50 Bn	2.67 Bn	-	-3,268.34%

Download Data